Antenatal prevention of fetal respiratory distress syndrome: a glimpse into the future

1. Howson C.P., Kinney M.V., McDougall L., Lawn J.E. World Health Organization born too soon. World Health Organization. Born too soon.The global action report on preterm birth. WHO; 2012.
2. Liu L., Oza S., Hogan D., Chu Y., Perin J., Zhu J. et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016; 388(10063): 3027-35.
3. Hyagriv N. Simhan et al. Practice management of preterm labor. 2016; 128(4}: 155-64. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 171: Management of preterm labor. Obstet. Gynecol. 2016; 128(4): e155-64.
4. Brownfoot F.C., Gagliardi D.I., Bain E., Middleton P., Crowther C.A. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst. Rev. 2013; (8): CD006764.
5. Lee B.H., Stoll B.J., McDonald S.A., Higgins R.D. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics. 2008; 121(2): 289-96.
6. ACOG Committee on Obstetric Practice. Antenatal corticosteroid therapy for fetal maturation. Obstet. Gynecol. 2017; 130(2): e102-9.
7. Crowley P.A. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am. J. Obstet. Gynecol. 1995; 173(1): 322-35.
8. Dehaene I., Page A.S., Page G.H. Association between antenatal corticosteroid administration-to-birth interval and outcomes of preterm neonates. Obstet. Gynecol. 2015; 126(4): 896.
9. Wilms F.F., Vis J.Y., Pattinaja D.A., Kuin R.A., Stam M.C., Reuvers J.M., Mol B.W. Relationship between the time interval from antenatal corticosteroid administration until preterm birth and the occurrence of respiratory morbidity. Am. J. Obstet. Gynecol. 2011; 205(1): 49. e1-49. e7.
10. Norman M., Piedvache A., Børch K., Huusom L.D., Bonamy A.E., Howell E.A. Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity among very preterm infants results from the EPICE cohort. JAMA Pediatr. 2017; 171(7): 678-86.
11. Birth P. Obstetric care consensus no. 6 summary: periviable birth. Obstet. Gynecol. 2017; 130(4): 926-8.
12. Rohan A.J. Survival and neurodevelopmental outcomes among periviable infants. Am. J. Matern. Nurs. 2017; 42(5): 301.
13. Mitsiakos G., Kovacs L., Papageorgiou A. Are antenatal steroids beneficial to severely growth restricted fetuses? J. Matern. Neonatal Med. 2013; 26(15):1496-9.
14. Morrison J.L., Botting K.J., Soo P.S., McGillick E.V., Hiscock J., Zhang S. et al. Antenatal steroids and the IUGR fetus: Are exposure and physiological effects on the lung and cardiovascular system the same as in normally grown fetuses? J. Pregnancy. 2012; 2012: 839656.
15. Wijnberger L.D., Bilardo C.M., Hecher K., Stigter R.H., Visser G.H. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet. Gynecol. 2004; 23(6): 584-9.
16. Kim W.J., Han Y.S., Ko H.S., Park I.Y., Shin J.C., Wie J.H. Antenatal corticosteroids and outcomes of preterm small-for-gestational-age neonates in a single medical center. Obstet. Gynecol. Sci. 2018; 61(1): 7-13.
17. Ljubić A., Cvetković M., Sulović V., Radunović N., Antonović O., Vukolić D. et al. New technique for artificial lung maturation. Direct intramuscular fetal corticosteroid therapy. Clin. Exp. Obstet. Gynecol. 1999;26(1): 16-9.
18. Babović I., Radojičić Z., Plešinac S., Kastratović Kotlica B., Sparić R. Direct intramuscular fetal or maternal antenatal corticosteroid therapy: short-time effects on fetal behavior and oxygenation: a comparative study. J. Matern. Neonatal Med. 2016; 29(19): 3213-7.
19. Utama D.P., Crowther C.A. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung matu ation where there is a risk of preterm birth. Cochrane Database Syst. Rev. 2018; (6): CD008981.
20. Dixon C.L., Too G., Saade G.R., Gyamfi-Bannerman C. Past and present: a review of antenatal corticosteroids and recommendations for late preterm birth steroids. Am. J. Perinatol. 2018; 35(13): 1241-50.
21. Asztalos E.V., Murphy K.E., Willan A.R., Matthews S.G., Ohlsson A., Saigal S. et al. Multiple courses of antenatal corticosteroids for preterm Birth study outcomes in children at 5 years of age (MACS-5). JAMA Pediatr. 2013; 167(12): 1102-10.
22. Murphy K.E., Hannah M.E., Willan A.R., Hewson S.A., Ohlsson A., Kelly E.N. et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet. 2008; 372(9656): 2143-51.
23. Asztalos E., Willan A., Murphy K., Matthews S., Ohlsson A., Saigal S. et al. Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5). BMC Pregnancy Childbirth. 2014; 14(1): 272.
24. Singh R.R., Cuffe J.S., Moritz K.M. Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. Clin. Exp. Pharmacol. Physiol. 2012; 39(11): 979-89.
25. Sheen J.M., Yu H.R., Tiao M.M., Chen C.C., Huang L.T., Chang H.Y., Tain Y.L. Prenatal dexamethasone-induced programmed hypertension and renal programming. Life Sci. 2015; 132: 41-8.
26. Moisiadis V.G., Matthews S.G. Glucocorticoids and fetal programming part 2: mechanisms. Nat. Rev. Endocrinol. 2014; 10(7): 403-11.
27. Tsiarli M.A., Rudine A., Kendall N., Pratt M.O., Krall R., Thiels E. et al. Antenatal dexamethasone exposure differentially affects distinct cortical neural progenitor cells and triggers long-term changes in murine cerebral architecture and behavior. Transl. Psychiatry. 2017; 7(6): e1153.
28. Borges S., Coimbra B., Soares-Cunha C., Ventura-Silva A.P., Pinto L., Carvalho M.M. et al. Glucocorticoid programing of the mesopontine cholinergic system. Front. Endocrinol. (Lausanne). 2013; 4: 190.
29. Miranda A., Sousa N. Maternal hormonal milieu influence on fetal brain development. Brain Behav. 2018; 8(2): e00920.
30. Um-Bergström M., Papadogiannakis N., Westgren M., Vinnars M.T. Antenatal corticosteroid treatment and placental pathology, with a focus on villous maturation. Acta Obstet. Gynecol. Scand. 2018; 97(1): 74-81.
31. Crowther C.A., Haslam R.R., Hiller J.E., Doyle L.W., Robinson J.S.; Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet. 2006; 367(9526):1913-9.
32. McKinlay C.J.D., Cutfield W.S., Battin M.R., Dalziel S.R., Crowther C.A., Harding J.E.; ACTORDS Follow-up Group. Mid-childhood bone mass after exposure to repeat doses of antenatal glucocorticoids: a randomized trial. Pediatrics. 2017; 139(5): e20164250.
33. McKinlay C.J., Cutfield W.S., Battin M.R., Dalziel S.R., Crowther C.A., Harding J.E.; ACTORDS Study Group. Cardiovascular risk factors in children after repeat doses of antenatal glucocorticoids: an RCT. Pediatrics. 2015; 135(2): e405-15.
34. Gervasi M.T., Romero R., Bracalente G., Erez O., Dong Z., Hassan S.S. et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: Evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. J. Perinat. Med. 2012; 40(4): 329-43.
35. Tita A.T.N., Jablonski K.A., Bailit J.L., Grobman W.A., Wapner R.J., Reddy U.M. et al. Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. Am. J. Obstet. Gynecol. 2018; 219(3): 296. e1-296. e8.
36. Yarbrough M.L., Gronowski A.M. Fetal lung maturity testing : the end of an era. 2014; 8: 509-15.
37. Beamon C., Carlson L., Rambally B., Berchuck S., Gearhart M., Hammett-Stabler C., Strauss R. Predicting neonatal respiratory morbidity by lamellar body count and gestational age. J. Perinat. Med. 2016; 44(6): 677-83.
38. Lu J., Gronowski A.M., Eby C. Lamellar body counts performed on automated hematology analyzers to assess fetal lung maturity. Lab. Med. 2008; 39(7): 419-23.
39. Welch R.A., Recanati M.A., Welch K.C., Shaw M.K. Maternal plasma LPCAT 1 mRNA correlates with lamellar body count. J. Perinat. Med. 2018; 46(4): 429-31.
40. Palacio M., Bonet-Carne E., Cobo T., Perez-Moreno A., Sabrià J., Richter J. et al. Prediction of neonatal respiratory morbidity by quantitative ultrasound lung texture analysis: a multicenter study. Am. J. Obstet. Gynecol. 2017; 217(2): 196. e1-196. e14.
41. Moshiri M., Mannelli L., Richardson M.L., Bhargava P., Dubinsky T.J. Fetal lung maturity assessment with MRI fetal lung-to-liver signal-intensity ratio. Am. J. Roentgenol. 2013; 201(6): 1386-90.
42. Bluml S., Rajagopalan V. Noninvasive estimation of fetal lung maturity with magnetic resonance spectroscopy. Am. J. Obstet. Gynecol. 2018; 219(2): 209-10.

Received 30.11.2018

Accepted 07.12.2018